Clinical experience with a monoclonal interleukin-2 receptor antibody (BT 563) for rejection therapy after orthotopic heart transplantation.
Iberer
F
F
Department of Transplantation, Karl-Franzens University, Graz, Austria.
Tscheliessnigg
K H
KH
Freigassner
M
M
Auer
T
T
Kleinert
R
R
Wasler
A
A
Petutschnigg
B
B
Müller
H
H
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000473:pathology / Q000628:therapy*; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab